Risks and safety of combination therapy for hypothyroidism
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Hypothyroidism is currently a condition that can be treated, but not cured. Although levothyroxine reverses stigmata of hypothyroidism in most individuals, some patients feel dissatisfied with 'monotherapy', and this has stimulated interest in 'combination therapy' with both levothyroxine and liothyronine. AREAS COVERED: A search of PubMed was conducted using terms including hypothyroidism, treatment, benefits, risks, and safety. Based on the articles identified, the body of evidence regarding the efficacy of traditional levothyroxine is reviewed. Concerns with levothyroxine therapy including impaired quality of life in treated patients, thyroxine-predominant hormone ratios, and inadvertent iatrogenic thyroid disease are discussed. The trials of combination therapy performed since 1999 were reviewed. The heterogeneity of these trials, both in terms of design and results, is discussed. The potential for new trials to determine whether combination therapy can reverse the dissatisfaction associated with monotherapy, while avoiding non-physiologic hormone ratios, inadvertent thyrotoxicosis, and unacceptable side effects is discussed. Expert commentary: Research regarding which therapy fully reverses hypothyroidism at a tissue and cellular level is ongoing. The field would be advanced by the development of an extended release preparation of liothyronine. In the future regeneration of functional thyroid follicles from stem cells may offer hope for curing hypothyroidism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although blood pressure is generally considered an important clinical outcome, this parameter did not show a between-group difference in any of the prior trials (104).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [104]
In the citing paper
“These measures have included body weight, lipid profile, blood pressure, sex hormone binding globulin, bone turnover markers, cardiac monitoring, bone mineral density, and neurocognitive function.”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [104]
In the citing paper
“Several biological outcomes and safety measures have been monitored in the combination therapy studies conducted thus far and would serve as secondary efficacy and safety outcomes (104).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [104]
In the citing paper
“Potential targets include FT4, total T3, FT3, and FT4/FT3 ratio (19).”
From Can Reverse T3 Assay Be Employed to Guide T4 vs. T4/T3 Therapy in Hypothyroidism? (2019) · cites this paper as [19]
In the citing paper
“Yet the notable inaccuracy of FT3 assays requires precaution when interpreting serial laboratory results (19, 20).”
From Can Reverse T3 Assay Be Employed to Guide T4 vs. T4/T3 Therapy in Hypothyroidism? (2019) · cites this paper as [19]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
Self-citationLaboratory Support for the Diagnosis and Monitoring of Thyroid Disease
(2003) · Thyroid · doi:10.1089/105072503321086962 · Cited by 1,212
Werner & Ingbar's the thyroid : a fundamental and clinical text
Werner, S. C., Ingbar, S. H., Braverman, L. E., & Utiger, R. D. (2012) · Lippincott-Raven eBooks · Cited by 1,016
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514
Bunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437
Flynn, R. W., Bonellie, S. R., Jung, R. T., MacDonald, T. M., Morris, A. D., & Leese, G. P. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1625 · Cited by 415
Generation of functional thyroid from embryonic stem cells
Antonica, F., Kasprzyk, D. F., Opitz, R., Iacovino, M., Liao, X.-H., Dumitrescu, A. M., Refetoff, S., Peremans, K., Manto, M., Kyba, M., et al. (2012) · Nature · doi:10.1038/nature11525 · Cited by 359
Panicker, V., Saravanan, P., Vaidya, B., Evans, J., Hattersley, A. T., Frayling, T. M., & Dayan, C. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1301 · Cited by 327
Harington, C. R., & Barger, G. (1927) · Biochemical Journal · doi:10.1042/bj0210169 · Cited by 319
Research works printed but not linked: 1
- Ma R, 2015, Front Endocrinol (Lausanne), 6, 56
Cited by
An Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction
Peterson, S. J., Cappola, A. R., Castro, M. R., Dayan, C. M., Farwell, A. P., Hennessey, J. V., Kopp, P. A., Ross, D. S., Samuels, M. H., Sawka, A. M., et al. (2018) · Thyroid · doi:10.1089/thy.2017.0681 · Cited by 231
Self-citationJonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0720 · Cited by 172
“Although blood pressure is generally considered an important clinical outcome, this parameter did not show a between-group difference in any of the prior trials (104).”
Self-citationReference intervals in the diagnosis of thyroid dysfunction: treating patients not numbers
Jonklaas, J., & Razvi, S. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30371-1 · Cited by 100
Self-citationOptimal thyroid hormone replacement
Jonklaas, J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab031 · Cited by 89
Self-citationJonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · European Thyroid Journal · doi:10.1159/000512970 · Cited by 78
Self-citationLiothyronine and Desiccated Thyroid Extract in the Treatment of Hypothyroidism
Idrees, T., Palmer, S., Maciel, R. M. B., & Bianco, A. C. (2020) · Thyroid® · doi:10.1089/thy.2020.0153 · Cited by 58
“This T3 spike creates practical problems for therapy with LT3-containing tablets (50,51).”
BackgroundThyroid hormones and derivatives: endogenous thyroid hormones and their targets
Köhrle, J. (2018) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7902-8_9 · Cited by 47
Physician Choice of Hypothyroidism Therapy: Influence of Patient Characteristics
Jonklaas, J., Tefera, E., & Shara, N. (2018) · Thyroid · doi:10.1089/thy.2018.0325 · Cited by 41
“Some caution needs to employed, as the risks of synthetic combination therapy have not been fully investigated (40).”
BackgroundSelf-citationSamuels, M. H., Kolobova, I., Antosik, M., Niederhausen, M., Purnell, J. Q., & Schuff, K. G. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00224 · Cited by 37
Samuels, M. H., Kolobova, I., Niederhausen, M., Purnell, J. Q., & Schuff, K. G. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01203 · Cited by 35
Ahluwalia, R., Baldeweg, S. E., Boelaert, K., Chatterjee, K., Dayan, C., Okosieme, O., Priestley, J., Taylor, P., Vaidya, B., Zammitt, N., et al. (2023) · Clinical Endocrinology · doi:10.1111/cen.14935 · Cited by 34
“66 At therapeutic doses, levothyroxine is safe, well ‐ tolerated, with rarely reported serious side effects.”
BackgroundSustained release T3 therapy: animal models and translational applications
Idrees, T., Price, J. D., Piccariello, T., & Bianco, A. C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00544 · Cited by 30
“However, prospective safety studies to evaluate potential long term undesirable cardiovascular and skeleton associated with such pharmacokinetics (PK) have not been performed (34).”
BackgroundDa Conceição, R. R., Fernandes, G. W., Fonseca, T. L., Bocco, B. M. L. C., & Bianco, A. C. (2018) · Thyroid · doi:10.1089/thy.2018.0205 · Cited by 23
“By adding LT3 to the LT4 regimen, it is expected that normalization of serum TSH will occur with a slightly lower serum T4 and slightly higher serum T3, as seen in humans (20) and rats (8,30,31).”
Bjerkreim, B. A., Hammerstad, S. S., Gulseth, H. L., Berg, T. J., Omdal, L. J., Lee-Ødegård, S., & Eriksen, E. F. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.816566 · Cited by 24
Jonklaas, J., Tefera, E., & Shara, N. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00031 · Cited by 23
“There is relatively little data available about the potential risks of combination therapy (35).”
BackgroundSelf-citationHoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2018) · Journal of Thyroid Research · doi:10.1155/2018/3239197 · Cited by 20
Can Reverse T3 Assay Be Employed to Guide T4 vs. T4/T3 Therapy in Hypothyroidism?
Gomes-Lima, C., Wartofsky, L., & Burman, K. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00856 · Cited by 15
“Potential targets include FT4, total T3, FT3, and FT4/FT3 ratio (19).”
BackgroundAshraf, H., Heydari, M., Shams, M., Zarshenas, M. M., Tavakoli, A., & Sayadi, M. (2022) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2022/5456855 · Cited by 13
“,e pathophysiology of persistent hypothyroid symptoms despite adequate hormone replacement therapy is not well understood [11, 12], and no definitive treatment is available [13, 14].”
BackgroundTriiodothyronine alongside levothyroxine in the management of hypothyroidism?
Gottwald-Hostalek, U., & Kahaly, G. J. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1984219 · Cited by 9
Penna, G. C., Bianco, A. C., & Ettleson, M. D. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad629 · Cited by 8
Balkrishna, A., Paliwal, R., Maity, M., Varshney, Y., Sinha, S., & Varshney, A. (2024) · Clinical Phytoscience · doi:10.1186/s40816-024-00371-0 · Cited by 8
“It has been reported from older as well as newer studies that up to 20% patients develop iatrogenic hyperthyroidism whereas another 20% are rendered hypothyroid [22].”
BackgroundInfluentialPawar, R. S., Sagi, S., & Leontyev, D. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3046 · Cited by 4
Mehran, L., Amouzegar, A., Foroutan, S. M., Masoumi, S., Tohidi, M., Abdi, H., Aghaei, A., Saghafinia, A. E., & Azizi, F. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01434-y · Cited by 6
“Serum TSH values in the previous clinical trials varied in patients under LT4 + LT3 combination therapy [25].”
ResultJonklaas, J. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2492789 · Cited by 2
“These choices are made difficult because of the peaks and troughs of T3 that occur depending on the chosen LT3 regimen [79].”
Self-citationPidchenko, N. S. (2020) · Український радіологічний та онкологічний журнал · doi:10.46879/ukroj.4.2020.387-402 · Cited by 1
“curacy of T3 tests should be carefully taken into consideration when interpreting serial laboratory results [27, 40].”
BackgroundInfluentialObese Women With Hypothyroidism Treated with Levothyroxine Have Reduced Resting Energy Expenditure
Samuels, M. H. (2020) · Clinical Thyroidology · doi:10.1089/ct.2020;32.218-220
Mehran, L., Amouzegar, A., Foroutan, S. M., Masoumi, S., Tohidi, M., Abdi, H., Aghaei, A., Saghafinia, A. E., & Azizi, F. (2024) · Figshare · doi:10.6084/m9.figshare.26613242
Metadata
- Authors
- Jonklaas, J.
- Affiliations
- Georgetown University (US)
- Corresponding author
- Jonklaas, Jacqueline
- ORCID
- Jonklaas, Jacqueline
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2016-05-09
- Volume
- 9
- Issue
- 8
- Pages
- 1057-1067
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W2347201063
- Cited by
- 27
- References
- 71
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 4 · 2019: 4 · 2018: 6 · 2017: 1
- FWCI
- 0.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- hypothyroidism, combination therapy, levothyroxine, liothyronine, iatrogenic hyperthyroidism, quality of life, treatment satisfaction, stem cell therapy
- MeSH terms
- Animals, Drug Therapy, Combination, Humans, Hypothyroidism, Quality of Life, Thyroxine, Triiodothyronine, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.